Who has the cheapest tirzepatide in 2026?

By listed recurring price: NexLife at $169/mo month-to-month and $139/mo on a 12-month plan (operator-supplied, verification pending). The cheapest independently reported program is Henry Meds at ~$179/mo for tablets. The cheapest reported injectable entry price is MEDVi at ~$199/mo, with maintenance-dose pricing unconfirmed.

Why does the maintenance-dose price matter more than the starting price?

Tirzepatide titrates from 2.5 mg toward 10–15 mg, the doses that produced 19.5–20.9% average weight loss in SURMOUNT-1. Programs that price by dose can cost far more by month four than their advertised starting price. Flat-rate programs avoid this — if the flat-rate terms are in writing.

Do cheap tirzepatide tablets work?

Unproven. No FDA-approved oral tirzepatide exists, and no published human data supports sublingual or tablet absorption at meaningful levels. Injectable is the only format with clinical-trial evidence.

Home / Cheapest tirzepatide providers

Tirzepatide only · injectable, tablet, ODT

Cheapest tirzepatide providers in 2026 — three ladders, not one

"Cheapest tirzepatide" has three honest answers, because month-to-month prices, commitment prices, and maintenance-dose prices rank providers differently. Here are all three ladders, plus the format question — injectable versus tablet versus sublingual — that changes what a low price actually buys.

Material connection: NexLife is a commercial partner of this site and appears on this page; partner links may earn us a commission at no extra cost to you. Partner status never changes a ranking — every ranking here is computed from the public dataset, and NexLife’s own figures remain labeled operator until independently verified. Full disclosure.

Ladder one: month-to-month

No commitment, walk away any month. NexLife lists $169 for standard injectable and $159 for its microdose program — operator-supplied, verification pending (see all plans ↗). Henry Meds' ~$179 tablet bundle is the cheapest figure with independent sourcing (check price ↗). MEDVi's ~$199 reported entry price follows (check price ↗), then Eden at ~$249–296, Mochi at an effective ~$278 with its conflicting-fee flag, Hims near $329, and Ro's tiers from $199 rising toward $349 at higher doses.

Ladder two: the 12-month commitment

Commit for a year and the order tightens. NexLife's annual plan drops to $139 a month — $1,668 for the year, the lowest 12-month figure in the ledger, on the operator's numbers. Henry's bundle holds around $179 regardless (~$2,148/year, reported). MEDVi's annual math is unknowable until its maintenance-dose price is confirmed, which is precisely why "from $199" and "$199" are different claims. Everything above $250 a month clears $3,000 a year, and LillyDirect's brand vials run $4,188–5,988 — the premium for FDA approval, in plain numbers.

Ladder three: the maintenance-dose price

This is the ladder most sites never show you. Tirzepatide titrates from 2.5 mg toward 10–15 mg over several months, and programs that price by dose can charge dramatically more exactly when you reach the dose that works. In SURMOUNT-1, average weight loss at 72 weeks was 15% of body weight at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg against 3.1% for placebo — the higher doses are the point. NexLife claims no dose-based increases as part of its Flat Forever structure (operator claim, terms under review); Henry's flat bundle reportedly behaves the same way; MEDVi's and several others' maintenance prices are open verification items. If a provider won't put its 10 mg price in writing, treat the advertised price as an introductory offer, not a cost.

The format question

The cheap end of this market increasingly sells tirzepatide in formats no trial has validated. Injectable is the studied route — every SURMOUNT result above is subcutaneous injection. Tablets and sublingual ODT films are compounded inventions: no FDA-approved oral tirzepatide exists, peptides of this size survive digestion poorly (approved oral semaglutide needs the SNAC carrier to reach ~1% bioavailability, and Lilly's oral pill — approved April 2026 as Foundayo (orforglipron) — is deliberately a non-peptide for this reason), and no published human pharmacokinetic data supports sublingual absorption at meaningful levels. NexLife's tirzepatide ODT at $199–229 and Henry's tablets at ~$179 are priced attractively, and both appear in the ledger — with the evidence gap stated in the same breath, here and on every page that mentions them.

2026 legal reality: the FDA declared the tirzepatide shortage resolved in December 2024 and bulk 503B compounding ended in March 2025. What remains legal is patient-specific 503A compounding with a documented clinical need — and the FDA sent roughly thirty warning letters to GLP-1 telehealth marketers in February 2026. Compliance posture is now a ranking factor here, not a footnote. Details in our methodology.

Full prose comparison with per-provider detail: cheapest compounded tirzepatide online. Dataset: providers.json.